Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

While You Were Out: News In Brief

Picture showing group of friends having fun with sparklers - Image

Related Content

Braeburn's Buprenorphine Clears Advisory Committee, But US FDA Likely To Limit Dosage

Nov 02 2017

Sublocade Approval Grows Indivior's Opioid Addiction Franchise In Competitive Market

Dec 02 2017

Alexion’s Son of Soliris Aims To Takes Dosing Right Down

Dec 08 2016

Pfizer Draws Curtain On Anti-infective Research; Refocuses On Next-gen Vaccines

May 13 2013

Anatomy Of A Biotech Company: Acorda Gets Dressed For A Second Act

Oct 17 2018

Braeburn's Buprenorphine Bid: Eight Dosing Options Part Of "All Hands On Deck" Approach

Jan 17 2018

Braeburn Gets CRL For CAM2038 In Opioid Use Disorder, Yields Ground To Indivior

Jan 23 2018

Roche's IMpower150 Gets AACR Applause But Merck's KEYNOTE-189 Big Winner

Apr 17 2018

AbbVie's Upadacitinib Safety Appears Improved In Largest, Longest RA Study

Apr 10 2018

Wellcome Trust Seeks 'Talent Scout' CEO For New Fund For Risky Health Ideas

Jul 11 2018

Roche, Bristol On The Defensive After Merck's Lung Cancer Wins At ASCO

Jun 06 2018

AbbVie Soothes Safety Fears With More Upadacitinib RA Data

Jun 07 2018

Related Companies

Apple Tree Partners

Indivior plc

AbbVie Inc.

Alexion Pharmaceuticals Inc.

Pfizer Inc.

Acorda Therapeutics, Inc.

Merck & Co., Inc.

More from Archive

More from Scrip

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window